TP53 mutations in human cancers: origins, consequences, and clinical use.

Cited by (1,002)

Items 401–500 of 1,002

1. A balancing act: using small molecules for therapeutic intervention of the p53 pathway in cancer
   Jessica J. Miller, Christian Gaiddon, Tim Storr · 2020 · Chemical Society Reviews
2. Emerging Roles of the Tumor Suppressor p53 in Metabolism
   Lili Yu, Meng Yin Wu, Gaoyang Zhu, Yang Xu · 2022 · Frontiers in Cell and Developmental Biology
3. Loss of p53 induces leukemic transformation in a murine model of Jak2 V617F-driven polycythemia vera
   Tsuruta-Kishino, T, Koya, J, Kataoka, K, Narukawa, K, Sumitomo, Y, Kobayashi, H, Sato, T, Kurokawa, M · 2017 · Oncogene
4. Mutant p53 drives an immune cold tumor immune microenvironment in oral squamous cell carcinoma
   Yewen Shi, Tongxin Xie, Bingbing Wang, Rong Wang, Yu Cai, Bo Yuan, Frederico O. Gleber‐Netto, Xiangjun Tian, Alanis Enid Rodriguez-Rosario, Abdullah A. Osman et al. · 2022 · Communications Biology
5. Targeted therapy for pancreatic ductal adenocarcinoma: Mechanisms and clinical study
   Heng‐Chung Kung, Jun Yu · 2023 · MedComm
6. FBXW7-mutated colorectal cancer cells exhibit aberrant expression of phosphorylated-p53 at Serine-15
   Ningning Li, Federica Lorenzi, Eliana Kalakouti, Makhliyo Normatova, Roya Babaei‐Jadidi, Ian P.M. Tomlinson, Abdolrahman Shams Nateri · 2015 · Oncotarget
7. iASPP inhibits p53-independent apoptosis by inhibiting transcriptional activity of p63/p73 on promoters of proapoptotic genes
   Yun Cai, Shi Qiu, Xing Gao, Shou-Zhi Gu, Ze-Jun Liu · 2012 · APOPTOSIS
8. Cancer heterogeneity: origins and implications for genetic association studies
   Davnah Urbach, Mathieu Lupien, Margaret Rita Karagas, Jason H. Moore · 2012 · Trends in Genetics
9. Lipoic acid induces p53-independent cell death in colorectal cancer cells and potentiates the cytotoxicity of 5-fluorouracil
   Bastian Dörsam, Anja Göder, Nina Seiwert, Bernd Kaina, Jörg Fahrer · 2014 · Archives of Toxicology
10. Pharmacological targeting of glucose-6-phosphate dehydrogenase in human erythrocytes by Bay 11–7082, parthenolide and dimethyl fumarate
    Mehrdad Ghashghaeinia, Daniela Giustarini, Pavla Kořalková, Martin Köberle, Kousi Alzoubi, Rosi Bissinger, Zohreh Hosseinzadeh, Peter Dreischer, Ingolf Bernhardt, Florian J.W. Lang et al. · 2016 · Scientific Reports
11. The Enigma of miRNA Regulation in Cancer
    Anjan K. Pradhan, Luni Emdad, Swadesh Kumar Das, Devanand Sarkar, Paul B. Fisher · 2017 · Advances in cancer research
12. New Insights into the Role of DNA Shape on Its Recognition by p53 Proteins
    Dmitrij Golovenko, Bastian Bräuning, Pratik Vyas, Tali E. Haran, H. Rozenberg, Zippora Shakked · 2018 · Structure
13. Intratumour heterogeneity of p53 expression; causes and consequences
    Yuezhen Xue, Boris San Luis, David Philip Lane · 2019 · The Journal of Pathology
14. TP53 Mutations Predict Sensitivity to Adjuvant Gemcitabine in Patients with Pancreatic Ductal Adenocarcinoma: Next-Generation Sequencing Results from the CONKO-001 Trial
    Marianne Sinn, Bruno Valentin Sinn, Denise Treue, Ulrich Keilholz, Frédérik Damm, Rosa Bianca Schmuck, Philipp Lohneis, Frederick Klauschen, Jana Käthe Striefler, Marcus Bahra et al. · 2020 · Clinical Cancer Research
15. The DNA damage checkpoint: A tale from budding yeast
    Paolo Pizzul, Erika Casari, Marco Gnugnoli, Carlo Rinaldi, Flavio Corallo, Maria Pia Longhese · 2022 · Frontiers in Genetics
16. Association of TP53 Mutational Status and Gender with Survival after Adjuvant Treatment for Stage III Colon Cancer: Results of CALGB 89803
    Robert S. Warren, Chloe Evelyn Atreya, Donna Niedzwiecki, VIVIAN K. WEINBERG, David B. Donner, Robert James Mayer, Richard M. Goldberg, Carolyn C. Compton, Marlene B. Zuraek, Cynthia Ye et al. · 2013 · Clinical Cancer Research
17. Therapeutic potential of p53 reactivation in prostate cancer: Strategies and opportunities
    Sangeeta Kumari, Vikas Sharma, Rahul Tiwari, Jay Prakash Maurya, Bharat Bhusan Subudhi, Dhirodatta Senapati · 2022 · European Journal of Pharmacology
18. HPV-related oropharyngeal cancers: From pathogenesis to new therapeutic approaches
    Maria Lina Tornesello, Francesco Perri, Luigi Buonaguro, Franco Ionna, Luigi Buonaguro, Francesco Caponigro · 2014 · Cancer Letters
19. SHARPIN Facilitates p53 Degradation in Breast Cancer Cells
    Huijie Yang, Sifan Yu, Weilong Wang, Xin Li, Yingxiang Hou, Zhenhua Liu, Yuanyuan Shi, Kun Mu, Gang Niu, Juntao Xu et al. · 2017 · Neoplasia
20. Mutant p53 establishes targetable tumor dependency by promoting unscheduled replication
    Shilpa Singh, Catherine A. Vaughan, Rebecca A. Frum, Steven R. Grossman, Sumitra Deb, Swati Palit Deb · 2017 · Journal of Clinical Investigation
21. HPV positive neuroendocrine cervical cancer cells are dependent on Myc but not E6/E7 viral oncogenes
    Hang Yuan, Ewa Krawczyk, Jan K. Blancato, Christopher Albanese, Dan Zhou, Naidong Wang, Siddartha Paul, Faris Alkhilaiwi, Nancy Palechor-Ceron, Aleksandra Dakic et al. · 2017 · Scientific Reports
22. Diverse p53/DNA binding modes expand the repertoire of p53 response elements
    Pratik Vyas, Itai Beno, Zhiqun Xi, Yan Stein, Dmitrij Golovenko, Naama Kessler, Varda Rotter, Zippora Shakked, Tali E. Haran · 2017 · Proceedings of the National Academy of Sciences
23. Recent Advances in Peptide-Based Approaches for Cancer Treatment
    Anne C. Conibear, Alanca Schmid, Meder Kamalov, Christian F. W. Becker, Claudia Bello · 2017 · Current Medicinal Chemistry
24. A high-throughput next-generation sequencing-based method for detecting the mutational fingerprint of carcinogens
    Ahmad Besarati Nia, Haiqing Li, Jae‐In Yoon, Albert Zheng, Hanlin Gao, Stella Tommasi · 2012 · Nucleic Acids Research
25. TP53 mutations induced by BPDE in Xpa-WT and Xpa-Null human TP53 knock-in (Hupki) mouse embryo fibroblasts
    Jill E. Kucab, Harry VAN STEEG, Mirjam Luijten, Heinz H. Schmeiser, Paul A. White, David H. Phillips, Volker Manfred Arlt · 2015 · Mutation research. Fundamental and molecular mechanisms of mutagenesis
26. Gain-of-function of mutant p53: mutant p53 enhances cancer progression by inhibiting KLF17 expression in invasive breast carcinoma cells
    Amjad Ali, Abdus Saboor Shah, Ayaz Ahmad · 2014 · Cancer Letters
27. Inhibiting MDM2-p53 Interaction Suppresses Tumor Growth in Patient-Derived Non–Small Cell Lung Cancer Xenograft Models
    Josephine Hai, Shingo Sakashita, Ghassan Allo, Olga Ludkovski, Christine Ng, Frances A. Shepherd, Ming‐Sound Tsao · 2015 · Journal of Thoracic Oncology
28. Porcine Models of Pancreatic Cancer
    Katie L. Bailey, Mark A. Carlson · 2019 · Frontiers in Oncology
29. Design and synthesis of anticancer 1-hydroxynaphthalene-2-carboxanilides with a p53 independent mechanism of action
    Ewelina Spaczyńska, Anna Mrozek‐Wilczkiewicz, Katarzyna Malarz, Jiří Kos, Tomáš Goněc, Michal Oravec, Robert Gawecki, Andrzej Bąk, Jana Doháňošová, Iva Kapustíková et al. · 2019 · Scientific Reports
30. Crotonylation at serine 46 impairs p53 activity
    Peng Liao, Nimisha Bhattarai, Bo Cao, Xiang Yu Zhou, Ji Hoon Jung, Krishna Damera, Taylor T. Fuselier, Suresh Thareja, William C. Wimley, Binghe Wang et al. · 2020 · Biochemical and Biophysical Research Communications
31. Gain-of-function p53 protein transferred via small extracellular vesicles promotes conversion of fibroblasts to a cancer-associated phenotype
    Shaolin Ma, Michael H. McGuire, Lingegowda Selanere Mangala, Sanghoon Lee, Elaine Stur, Wen Si Hu, Emine Bayraktar, Alejandro Villar‐Prados, Cristina Ivan, Sherry Y. Wu et al. · 2021 · Cell Reports
32. DNAJA1 promotes cancer metastasis through interaction with mutant p53
    Atsushi Kaida, Satomi Yamamoto, Alejandro Parrales, Eric D. Young, Atul Ranjan, Mohamed A. Alalem, Keiichi Morita, Yu Oikawa, Hiroyuki Harada, Tohru Ikeda et al. · 2021 · Oncogene
33. Mitogen‐activated protein kinase‐activated protein kinase‐2 (MK2) and its role in cell survival, inflammatory signaling, and migration in promoting cancer
    Deri Morgan, Kiersten L. Berggren, Colby Spiess, Hannah M. Smith, Ajay Tejwani, Scott James Weir, Christopher E. Lominska, Sufi Mary Thomas, Gregory N. Gan · 2021 · Molecular Carcinogenesis
34. Recent advances and challenges of rare variant association analysis in the biobank sequencing era
    Wenan Chen, Brandon J. Coombes, Nicholas Bradley Larson · 2022 · Frontiers in Genetics
35. The crisscross between p53 and metabolism in cancer
    Youxiang Mao, Peng Jiang · 2023 · Acta Biochimica et Biophysica Sinica
36. Prevalence and impact of founder mutations in hereditary breast cancer in Latin America
    Patrícia Ashton‐Prolla, Fernando Regla Vargas · 2014 · Genetics and Molecular Biology
37. Reactivation of p53 as therapeutic intervention for malignant melanoma
    Aart G. Jochemsen · 2013 · Current Opinion in Oncology
38. Restoring the tumour suppressive function of p53 as a parallel strategy in melanoma therapy
    Min M. Lu, Paul F. Miller, Xin Lü · 2014 · FEBS Letters
39. Identification of a novel p53 target, COL17A1, that inhibits breast cancer cell migration and invasion
    Varalee Yodsurang, Chizu Tanikawa, Takafumi Miyamoto, Paulisally Hau Yi Lo, Makoto Hirata, Koichi Matsuda · 2017 · Oncotarget
40. Role of Mycoplasma Chaperone DnaK in Cellular Transformation
    Francesca Benedetti, Fiorenza Cocchi, Olga Latinovic, Sabrina Curreli, Selvi Krishnan, Arshi Munawwar, Robert C. Gallo, Davide Zella · 2020 · International Journal of Molecular Sciences
41. The evolution of multicellularity and cancer: views and paradigms
    Aurora M. Nedelcu · 2020 · Biochemical Society Transactions
42. Targeting P53 as a Future Strategy to Overcome Gemcitabine Resistance in Biliary Tract Cancers
    Chiao‐En Wu, Yi‐Ru Pan, Chun‐Nan Yeh, John Lunec · 2020 · Biomolecules
43. Emerging Pharmacotherapeutic Strategies to Overcome Undruggable Proteins in Cancer
    Yuqing Lu, Yuewen Yang, Guanghao Zhu, Hairong Zeng, Yi‐Ming Fan, Fujia Guo, Dongshu Xu, Boya Wang, Dapeng Chen, Guang‐Bo Ge · 2023 · International Journal of Biological Sciences
44. A pancancer analysis of the oncogenic role of cyclin B1 (CCNB1) in human tumors
    Peng Dai, Lecai Xiong, Yanhong Wei, Xiaoyan Wei, Xuefeng Zhou, Jinping Zhao, Hexiao Tang · 2023 · Scientific Reports
45. Emerging biomarkers and molecular targets for precision medicine in cervical cancer
    Pankaj Garg, Madhu Krishna, Ayalur Raghu Subbalakshmi, Sravani Keerthi Ramisetty, Atish Ranjan Mohanty, Prakash Kulkarni, David A. Horne, Ravi Salgia, Sharad S. Singhal · 2024 · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer
46. Molecular diagnosis of nasopharyngeal carcinoma: Past and future
    Cheng–Lung Hsu, Yu‐Sun Chang, Hsin‐Pai Li · 2024 · Biomedical Journal
47. p53 Transactivation and the Impact of Mutations, Cofactors and Small Molecules Using a Simplified Yeast-Based Screening System
    Virginia Andreotti, Yari Ciribilli, Paola Monti, Alessandra Bisio, Mattia Lion, Jennifer Jordan, Gilberto Fronza, Paola Menichini, Michael A. Resnick, Alberto Inga · 2011 · PLoS ONE
48. Piperlongumine exerts cytotoxic effects against cancer cells with mutant p53 proteins at least in part by restoring the biological functions of the tumor suppressor
    Debasish Basak, Surendra Reddy Punganuru, Kalkunte S. Srivenugopal · 2016 · International Journal of Oncology
49. The Hippo pathway, p53 and cholesterol
    Yael Aylon, Moshe Oren · 2016 · Cell Cycle
50. Journey of TRAIL from bench to bedside and its potential role in immuno-oncology
    George E. Naoum, Donald J. Buchsbaum, Fady Tawadros, Ammad Ahmad Farooqı, Waleed O. Arafat · 2017 · Oncology Reviews
51. Wild type p53 function in p53Y220C mutant harboring cells by treatment with Ashwagandha derived anticancer withanolides: bioinformatics and experimental evidence
    Durai Sundar, Yue Yu, Shashank Prakash Katiyar, Jayarani Fatimah Putri, Jaspreet Kaur Dhanjal, Jia Wang, Anissa Nofita Sari, Evangelos Kolettas, Sunil C. Kaul, Renu Wadhwa · 2019 · Journal of Experimental & Clinical Cancer Research
52. Interplay between HSF1 and p53 signaling pathways in cancer initiation and progression: non-oncogene and oncogene addiction
    Agnieszka Toma-Jonik, Natalia Vydra, Patryk Janus, Wiesława Widłak · 2019 · Cellular Oncology
53. 6-Phosphofructo-2-Kinase/Fructose-2,6-Biphosphatase-2 Regulates TP53-Dependent Paclitaxel Sensitivity in Ovarian and Breast Cancers
    Hailing Yang, Shu Zhang, Yongying Jiang, Weiqun Mao, Lan Pang, Abena B. Redwood, Sabrina L. Jeter-Jones, Nicholas B. Jennings, Argentina Ornelas, Jinhua Zhou et al. · 2019 · Clinical Cancer Research
54. The role of TP53 gain-of-function mutation in multifocal glioblastoma
    Lauren R. Olafson, Manuri P. Gunawardena, Sheri Nixdorf, Kerrie Leanne McDonald, Robert W. Rapkins · 2020 · Journal of Neuro-Oncology
55. DNA-PK Inhibitor Peposertib Amplifies Radiation-Induced Inflammatory Micronucleation and Enhances TGFβ/PD-L1 Targeted Cancer Immunotherapy
    Michael I. Carr, Li-Ya Chiu, Yige Guo, Chunxiao Xu, Adam S. Lazorchak, Huakui Yu, Guozhong Qin, Jin Qi, Bo Marelli, Yan Lan et al. · 2022 · Molecular Cancer Research
56. Overview of Risk Factors for Esophageal Squamous Cell Carcinoma in China
    Erica Celeste Conway, Haisheng Wu, Linwei Tian · 2023 · Cancers
57. Multiplexed assays of variant effect for clinical variant interpretation
    Abbye E. McEwen, Malvika Tejura, Shawn Fayer, Lea M. Starita, Douglas M. Fowler · 2025 · Nature Reviews Genetics
58. Characterization of p53 expression in rainbow trout
    Michelle Liu, Catherine Tee, Fanxing Zeng, James P. Sherry, Brian Dixon, Niels C. Bols, Bernard P. Duncker · 2011 · Comparative Biochemistry and Physiology Part C Toxicology & Pharmacology
59. A high resolution genomic portrait of bladder cancer: correlation between genomic aberrations and the DNA damage response
    Troels Schepeler, Philippe Lamy, V Hvidberg, Jens R. Laurberg, Niels Fristrup, Thomas Reinert, Jiřina Bártková, Laurence Tropia, Jiří Bártek, Thanos D. Halazonetis et al. · 2012 · Oncogene
60. Role of E542 and E545 missense mutations of PIK3CA in breast cancer: a comparative computational approach
    D. Thirumal Kumar, C. George Priya Doss · 2016 · Journal of Biomolecular Structure and Dynamics
61. Mutant p53 upregulates alpha-1 antitrypsin expression and promotes invasion in lung cancer
    Reshma Shakya, Gerard A. Tarulli, L Sheng, Noor A. Lokman, Carmela Ricciardelli, Kathleen I. Pishas, C.I. Selinger, Maija R.J. Kohonen‐Corish, Wendy A. Cooper, Andrew G. Turner et al. · 2017 · Oncogene
62. Synergistic Rescue of Nonsense Mutant Tumor Suppressor p53 by Combination Treatment with Aminoglycosides and Mdm2 Inhibitors
    Meiqiongzi Zhang, Angelos Heldin, Mireia Palomar-Siles, Susanne Öhlin, Vladimir J.N. Bykov, Klas G. Wiman · 2018 · Frontiers in Oncology
63. Review of Prognostic Expression Markers for Clear Cell Renal Cell Carcinoma
    Florent Petitprez, Mira Ayadi, Aurélien de Reyniès, Wolf H. Fridman, Catherine Sautès‐Fridman, Sylvie Job · 2021 · Frontiers in Oncology
64. Retrospective analysis of somatic mutations and clonal hematopoiesis in astronauts
    Agnieszka Brojakowska, Anupreet Kour, Mark Charles Thel, Eunbee Park, Malik Bisserier, Venkata Naga Srikanth Garikipati, Lahouaria Hadri, Paul J. Mills, Kenneth Walsh, David A. Goukassian · 2022 · Communications Biology
65. The Double-Edged Sword of SIRT3 in Cancer and Its Therapeutic Applications
    Shumin Ouyang, Qiyi Zhang, Linlin Lou, Kai Zhu, Zeyu Li, Peiqing Liu, Xiaolei Zhang · 2022 · Frontiers in Pharmacology
66. Targeting Protein–Protein Interfaces with Peptides: The Contribution of Chemical Combinatorial Peptide Library Approaches
    Alessandra Monti, Luigi Vitagliano, Andrea Caporale, Menotti Ruvo, Nunzianna Doti · 2023 · International Journal of Molecular Sciences
67. The Interplay between T Cells and Cancer: The Basis of Immunotherapy
    Christina Chen, Xin Liu, Che‐Yu Chang, Helen Y. Wang, Rong‐Fu Wang · 2023 · Genes
68. Whole-genome sequencing analysis of phenotypic heterogeneity and anticipation in Li–Fraumeni cancer predisposition syndrome
    Hany Ariffin, Pierre L. Hainaut, Anna M. Puzio‐Kuter, Soo Sin Choong, Adelyne Sue Li Chan, Denis Tolkunov, Gunaretnam Rajagopal, Wenfeng Kang, Leon Li Wen Lim, Shekhar Krishnan et al. · 2014 · Proceedings of the National Academy of Sciences
69. Your neighbours matter – non-autonomous control of apoptosis in development and disease
    Matthew Eroglu, W. Brent Derry · 2016 · Cell Death and Differentiation
70. Coexistence of her2, ki67, and p53 in osteosarcoma: A strong prognostic factor
    Mahtab Rahbar, Keykhosro Mardanpour, Sourena Mardanpour · 2016 · North American Journal of Medical Sciences
71. Precision medicine in age-specific non-small-cell-lung-cancer patients: Integrating biomolecular results into clinical practice—A new approach to improve personalized translational research
    Tiziana Vavalà, Valentina Monica, Marco Lo Iacono, Teresa Mele, Simone Busso, Luisella Righi, Mauro Giulio Papotti, Giorgio V. Scagliotti, Silvia Novello · 2016 · Lung Cancer
72. Cancer adaptations: Atavism, de novo selection, or something in between?
    Frédéric Thomas A, Beáta Újvári, F. Renaud, Mark David Vincent · 2017 · BioEssays
73. Blocking mutation independent p53 aggregation by emodin modulates autophagic cell death pathway in lung cancer
    Ejazul Haque, Mohd Kamil, Safia Irfan, Saba Sheikh, Adria Hasan, Aamir Nazir, Snober Shabnam Mir · 2018 · The International Journal of Biochemistry & Cell Biology
74. Multiplex precise base editing in cynomolgus monkeys
    Wenhui Zhang, Tomomi Aida, Ricardo C.H. del Rosario, Jonathan J. Wilde, Chenhui Ding, Xiaohui Zhang, Zulqarnain Baloch, Yan Huang, Yu Tang, Duanduan Li et al. · 2020 · Nature Communications
75. Zebrafish Models for Human Cancer
    Heather R. Shive · 2012 · Veterinary Pathology
76. Clinical use of Molecular Data in Thyroid Nodules and Cancer
    Ali Saeed Alzahrani · 2023 · The Journal of Clinical Endocrinology & Metabolism
77. The Impact of p53 Dysfunction in ATR Inhibitor Cytotoxicity and Chemo- and Radiosensitisation
    Fiona K. Middleton, John Robert Pollard, Nicola J. Curtin · 2018 · Cancers
78. NMR characterization of solvent accessibility and transient structure in intrinsically disordered proteins
    Christoph Hartlmüller, Emil Spreitzer, Christoph Göbl, Salvatore Fabio Falsone, Tobias Madl · 2019 · Journal of Biomolecular NMR
79. Therapeutic targeting of TP53-mutated acute myeloid leukemia by inhibiting HIF-1α with echinomycin
    Wang, Yin, Liu, Yan, Bailey, Christopher, Zhang, Huixia, He, Miao, Sun, Duxin, Zhang, Peng, Parkin, Brian, Baer, Maria R., Zheng, Pan et al. · 2020 · Oncogene
80. Molecular events in the pathogenesis of vulvar squamous cell carcinoma
    Deyin Xing, Oluwole Fadare · 2020 · Seminars in Diagnostic Pathology
81. On the role of p53 in the cellular response to aneuploidy
    Akshay Narkar, Blake A. Johnson, Pandurang Bharne, Jin Zhu, Veena Padmanaban, Debojyoti Biswas, Andrew K. Fraser, Pablo A. Iglesias, Andrew J. Ewald, Rong Li · 2021 · Cell Reports
82. Targeting PSAT1 to mitigate metastasis in tumors with p53-72Pro variant
    Jingwen Jiang, Hai‐Ning Chen, Ping Jin, Li Zhou, Liyuan Peng, Zhao Huang, Siyuan Qin, Bowen Li, Hui Ming, Maochao Luo et al. · 2023 · Signal Transduction and Targeted Therapy
83. Genetically Engineered Mice as Experimental Tools to Dissect the Critical Events in Breast Cancer
    Mitchell E. Menezes, Swadesh Kumar Das, Luni Emdad, Jolene J. Windle, Xiang‐Yang Wang, Devanand Sarkar, Paul B. Fisher · 2014 · Advances in cancer research
84. How the environment shapes cancer genomes
    Gerd P. Pfeifer · 2014 · Current Opinion in Oncology
85. Mutant p53R270H drives altered metabolism and increased invasion in pancreatic ductal adenocarcinoma
    Heather K. Schofield, Jörg Zeller, Carlos E. Espinoza, Christopher J. Halbrook, Annachiara Del Vecchio, Brian Magnuson, Tania Fabo, Ayse Ece Cali Daylan, Ilya Kovalenko, Ho‐Joon Lee et al. · 2018 · JCI Insight
86. Helicobacter pylori induces somatic mutations in TP 53 via overexpression of CHAC 1 in infected gastric epithelial cells
    Yuriko Wada, Kosuke null Takemura, Padmaja Tummala, Keisuke Uchida, Keisuke Kitagaki, Asuka Furukawa, Yuuki Ishige, Takashi Ito, Yukichi Hara, Takashige Suzuki et al. · 2018 · FEBS Open Bio
87. Dying to Survive—The p53 Paradox
    Andrea Lees, Tamas Sessler, Simon S. McDade · 2021 · Cancers
88. Inflammatory Angiogenesis and the Tumor Microenvironment as Targets for Cancer Therapy and Prevention
    Antonino Bruno, Arianna Pagani, Elena Magnani, Teresa Rossi, Douglas McClain Noonan, Anna Rita Cantelmo, Adriana Albini · 2013 · Cancer treatment and research
89. Unbalancing p53/Mdm2/IGF-1R axis by Mdm2 activation restrains the IGF-1-dependent invasive phenotype of skin melanoma
    Claire Worrall, Naida Suleymanova, Caitrin Crudden, Iara Trocoli Drakensjo, Elisabeta Candrea, Daniela Nedelcu, S-I Takahashi, Leonard Girnita, Ada Girnita · 2017 · Oncogene
90. Effect of the Large and Small T-Antigens of Human Polyomaviruses on Signaling Pathways
    Ugo Lionel Moens, Andrew Macdonald · 2019 · International Journal of Molecular Sciences
91. Overview of major molecular alterations during progression from Barrett's esophagus to esophageal adenocarcinoma
    Irina Kalatskaya · 2016 · Annals of the New York Academy of Sciences
92. Synthetic lethality in lung cancer and translation to clinical therapies
    Ada W.Y. Leung, Tanya de Silva, Marcel B. Bally, William Wirt Lockwood · 2016 · Molecular Cancer
93. P53-MDM2 Pathway: Evidences for A New Targeted Therapeutic Approach in B-Acute Lymphoblastic Leukemia
    Stefania Trino, Luciana De Luca, Ilaria Laurenzana, Antonella Caivano, Luigi Del Vecchio, Giovanni Martinelli, Pellegrino Musto · 2016 · Frontiers in Pharmacology
94. Phase I trial of WEE1 inhibition with chemotherapy and radiotherapy as adjuvant treatment, and a window of opportunity trial with cisplatin in patients with head and neck cancer: the WISTERIA trial protocol
    Anthony H. Kong, James S. Good, Amanda J. Kirkham, Joshua Savage, Rhys Mant, Laura Llewellyn, Joanna L. Parish, Rachel J. Spruce, Martin David Forster, Stefano Schipani et al. · 2020 · BMJ Open
95. Demethylase-independent function of JMJD2D as a novel antagonist of p53 to promote Liver Cancer initiation and progression
    Ming Li, Yuan Deng, Minghui Zhuo, Hui Zhou, Xu Kong, Xiaogang Xia, Zhaojie Su, Qiang Chen, Peng Guo, Pingli Mo et al. · 2020 · Theranostics
96. Pharmacokinetic–pharmacodynamic guided optimisation of dose and schedule of CGM097, an HDM2 inhibitor, in preclinical and clinical studies
    Sebastian Bauer, George D. Demetri, Ensar Halilovic, Reinhard Dummer, Christophe Meille, Daniel Shao-Weng Tan, Nelson Guerreiro, Astrid Jullion, Stéphane Ferretti, Sébastien Jeay et al. · 2021 · British Journal of Cancer
97. Alterations in key signaling pathways in sinonasal tract melanoma. A molecular genetics and immunohistochemical study of 90 cases and comprehensive review of the literature
    Małgorzata Chłopek, Jerzy P. Lasota, Lester D.�R. Thompson, Magdalena Szczepaniak, Alina Kuźniacka, Kinga Hińcza, Kamila Kubicka, Maciej Kaczorowski, Michael Newford, Yalan Liu et al. · 2022 · Modern Pathology
98. Lead optimization of novel p53-MDM2 interaction inhibitors possessing dihydroimidazothiazole scaffold
    Masaki Miyazaki, Hiroyuki Naito, Yuuichi Sugimoto, Haruko C. Kawato, Tooru Okayama, Hironari Shimizu, Masaya Miyazaki, Mayumi Kitagawa, Takahiko Seki, Setsuko Fukutake et al. · 2012 · Bioorganic & Medicinal Chemistry Letters
99. BI-907828, a novel potent MDM2 inhibitor, inhibits glioblastoma brain tumor stem cells in vitro and prolongs survival in orthotopic xenograft mouse models
    Hao, Xiaoguang, Bahia, Ravinder K, Cseh, Orsolya, Bozek, Danielle A, Blake, Sophia, Rinnenthal, Jörg, Weyer-Czernilofsky, Ulrike, Rudolph, Dorothea, Artee Luchman, H · 2023 · Neuro-Oncology
100. Establishing Linkages Among DNA Damage, Mutagenesis, and Genetic Diseases
     Ashis K. Basu, John M. Essigmann · 2022 · Chemical Research in Toxicology